[A15-35] Ruxolitinib (Addendum to Commission A15-13)
Last updated 15.10.2015
Project no.:
A15-35
Commission:
Commission awarded on 26.08.2015 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A15-13 | Ruxolitinib – Benefit assessment according to §35a Social Code Book V (dossier assessment) | Commission completed |
Federal Joint Committee (G-BA)
2015-10-15 A G-BA decision was published.